 Kimberley Bruce
Concepts (284)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Microglia | 6 | 2025 | 251 | 3.200 |
Why?
| | Alzheimer Disease | 4 | 2025 | 560 | 1.930 |
Why?
| | Lipoproteins | 4 | 2025 | 168 | 1.730 |
Why?
| | Lipid Metabolism | 4 | 2025 | 518 | 1.570 |
Why?
| | Muromegalovirus | 9 | 2022 | 23 | 1.340 |
Why?
| | Brain | 6 | 2025 | 2677 | 1.260 |
Why?
| | Fatty Liver | 4 | 2018 | 243 | 1.110 |
Why?
| | Lipoprotein Lipase | 4 | 2022 | 59 | 0.980 |
Why?
| | Herpesviridae Infections | 8 | 2024 | 147 | 0.960 |
Why?
| | Non-alcoholic Fatty Liver Disease | 3 | 2019 | 279 | 0.940 |
Why?
| | Fructose | 1 | 2025 | 112 | 0.880 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2019 | 605 | 0.860 |
Why?
| | Metabolic Syndrome | 3 | 2011 | 354 | 0.760 |
Why?
| | Fatty Acids | 2 | 2022 | 443 | 0.760 |
Why?
| | Neuroglia | 1 | 2022 | 173 | 0.710 |
Why?
| | Optical Imaging | 1 | 2021 | 64 | 0.700 |
Why?
| | Lipid Droplets | 1 | 2021 | 23 | 0.700 |
Why?
| | Glucose Intolerance | 1 | 2022 | 146 | 0.690 |
Why?
| | Membrane Glycoproteins | 4 | 2025 | 500 | 0.690 |
Why?
| | Neurodegenerative Diseases | 2 | 2021 | 135 | 0.670 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 445 | 0.650 |
Why?
| | DNA Methylation | 2 | 2023 | 643 | 0.640 |
Why?
| | Circadian Clocks | 4 | 2019 | 50 | 0.630 |
Why?
| | Receptors, Immunologic | 3 | 2025 | 216 | 0.620 |
Why?
| | Diet, High-Fat | 8 | 2019 | 247 | 0.600 |
Why?
| | Animals | 36 | 2025 | 36951 | 0.590 |
Why?
| | Neurons | 3 | 2022 | 1590 | 0.570 |
Why?
| | Genes, Essential | 4 | 2014 | 23 | 0.530 |
Why?
| | CLOCK Proteins | 1 | 2016 | 8 | 0.510 |
Why?
| | Sirtuin 1 | 1 | 2016 | 30 | 0.500 |
Why?
| | Mice | 28 | 2024 | 17794 | 0.490 |
Why?
| | Disease Models, Animal | 8 | 2024 | 4295 | 0.490 |
Why?
| | Disease Susceptibility | 1 | 2018 | 347 | 0.490 |
Why?
| | Maternal Nutritional Physiological Phenomena | 4 | 2014 | 176 | 0.480 |
Why?
| | Sirtuin 3 | 1 | 2016 | 61 | 0.470 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2012 | 54 | 0.460 |
Why?
| | Cytomegalovirus Infections | 3 | 2022 | 192 | 0.460 |
Why?
| | Dietary Fats | 3 | 2016 | 304 | 0.450 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 697 | 0.440 |
Why?
| | Dendritic Cells | 4 | 2021 | 483 | 0.410 |
Why?
| | 14-3-3 Proteins | 1 | 2012 | 18 | 0.380 |
Why?
| | Mice, Inbred C57BL | 12 | 2024 | 5764 | 0.370 |
Why?
| | Phospholipids | 2 | 2025 | 223 | 0.370 |
Why?
| | Viral Proteins | 3 | 2024 | 342 | 0.350 |
Why?
| | Lipogenesis | 2 | 2009 | 61 | 0.330 |
Why?
| | Liver | 3 | 2016 | 1943 | 0.320 |
Why?
| | Mitochondria, Liver | 1 | 2009 | 73 | 0.310 |
Why?
| | Epigenesis, Genetic | 2 | 2011 | 660 | 0.310 |
Why?
| | Virus Replication | 3 | 2021 | 483 | 0.300 |
Why?
| | Salivary Glands | 4 | 2021 | 33 | 0.290 |
Why?
| | Olfactory Mucosa | 3 | 2024 | 38 | 0.280 |
Why?
| | Suprachiasmatic Nucleus | 2 | 2019 | 16 | 0.270 |
Why?
| | Killer Cells, Natural | 2 | 2024 | 449 | 0.270 |
Why?
| | Lymph Nodes | 4 | 2021 | 491 | 0.270 |
Why?
| | Virus Internalization | 3 | 2021 | 49 | 0.260 |
Why?
| | Rhadinovirus | 2 | 2024 | 20 | 0.260 |
Why?
| | Gene Expression Regulation | 5 | 2021 | 2607 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2024 | 1091 | 0.260 |
Why?
| | Pregnancy | 9 | 2019 | 6771 | 0.260 |
Why?
| | Humans | 26 | 2025 | 137782 | 0.250 |
Why?
| | Energy Metabolism | 1 | 2012 | 922 | 0.250 |
Why?
| | Triglycerides | 3 | 2023 | 524 | 0.250 |
Why?
| | Apolipoprotein E4 | 1 | 2025 | 37 | 0.230 |
Why?
| | Central Nervous System | 2 | 2024 | 258 | 0.230 |
Why?
| | Trigeminal Ganglion | 1 | 2024 | 25 | 0.230 |
Why?
| | Receptors, Interferon | 1 | 2024 | 52 | 0.210 |
Why?
| | Herpes Simplex | 1 | 2024 | 95 | 0.210 |
Why?
| | Herpesvirus 1, Human | 1 | 2024 | 87 | 0.210 |
Why?
| | Interferon-gamma | 2 | 2024 | 789 | 0.210 |
Why?
| | Mice, Inbred BALB C | 6 | 2021 | 1272 | 0.210 |
Why?
| | Phenotype | 4 | 2021 | 3196 | 0.200 |
Why?
| | Lipodystrophy | 1 | 2022 | 13 | 0.200 |
Why?
| | Hypertriglyceridemia | 1 | 2022 | 39 | 0.190 |
Why?
| | Circadian Rhythm | 3 | 2016 | 468 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 146 | 0.190 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1775 | 0.190 |
Why?
| | Diet | 3 | 2023 | 1279 | 0.190 |
Why?
| | Cytomegalovirus Vaccines | 1 | 2021 | 3 | 0.180 |
Why?
| | Superinfection | 1 | 2021 | 6 | 0.180 |
Why?
| | Acinar Cells | 1 | 2021 | 13 | 0.180 |
Why?
| | Herpesviridae | 1 | 2021 | 23 | 0.180 |
Why?
| | Tissue Adhesions | 2 | 2012 | 32 | 0.180 |
Why?
| | Chemokines, CC | 1 | 2021 | 33 | 0.180 |
Why?
| | Obesity | 4 | 2018 | 2993 | 0.180 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2021 | 17 | 0.180 |
Why?
| | Substrate Specificity | 1 | 2021 | 372 | 0.170 |
Why?
| | Estrogens | 1 | 2024 | 367 | 0.170 |
Why?
| | Herpesvirus 3, Human | 1 | 2024 | 332 | 0.170 |
Why?
| | Ultracentrifugation | 1 | 2020 | 52 | 0.170 |
Why?
| | Cytomegalovirus | 1 | 2021 | 157 | 0.170 |
Why?
| | Inflammation | 4 | 2021 | 2838 | 0.170 |
Why?
| | Recombination, Genetic | 1 | 2021 | 204 | 0.170 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 365 | 0.160 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 295 | 0.160 |
Why?
| | Cell Death | 1 | 2021 | 374 | 0.160 |
Why?
| | Tobramycin | 1 | 2019 | 52 | 0.160 |
Why?
| | Female | 17 | 2024 | 73465 | 0.160 |
Why?
| | Lipopolysaccharides | 1 | 2023 | 886 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 220 | 0.160 |
Why?
| | Astrocytes | 1 | 2021 | 210 | 0.160 |
Why?
| | Hypothalamus | 2 | 2017 | 153 | 0.160 |
Why?
| | Exosomes | 1 | 2020 | 103 | 0.160 |
Why?
| | Lipids | 2 | 2021 | 673 | 0.150 |
Why?
| | Photoperiod | 2 | 2016 | 52 | 0.150 |
Why?
| | Insulin Resistance | 2 | 2022 | 1211 | 0.150 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 611 | 0.150 |
Why?
| | Cholesterol | 1 | 2021 | 410 | 0.150 |
Why?
| | Quinolines | 1 | 2019 | 178 | 0.150 |
Why?
| | Viral Envelope Proteins | 1 | 2019 | 84 | 0.140 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.140 |
Why?
| | Precision Medicine | 1 | 2022 | 433 | 0.140 |
Why?
| | Cell Line | 2 | 2021 | 2847 | 0.140 |
Why?
| | Pseudomonas aeruginosa | 1 | 2019 | 352 | 0.130 |
Why?
| | Pravastatin | 1 | 2017 | 41 | 0.130 |
Why?
| | Simvastatin | 1 | 2017 | 61 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2016 | 4 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2016 | 3 | 0.130 |
Why?
| | Glucose | 2 | 2022 | 1020 | 0.130 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 57 | 0.120 |
Why?
| | Muscular Diseases | 1 | 2017 | 114 | 0.120 |
Why?
| | Hyperlipidemias | 1 | 2017 | 120 | 0.120 |
Why?
| | Fibrosis | 1 | 2019 | 552 | 0.120 |
Why?
| | Maternal Exposure | 1 | 2018 | 190 | 0.120 |
Why?
| | Interferon Type I | 1 | 2016 | 140 | 0.120 |
Why?
| | Acidosis | 1 | 2017 | 101 | 0.120 |
Why?
| | Macrophages | 3 | 2024 | 1549 | 0.120 |
Why?
| | Body Composition | 2 | 2017 | 684 | 0.120 |
Why?
| | Immunity, Innate | 2 | 2021 | 828 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1060 | 0.110 |
Why?
| | Lung | 4 | 2024 | 4060 | 0.110 |
Why?
| | Nanoparticles | 1 | 2020 | 482 | 0.110 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2014 | 13 | 0.110 |
Why?
| | Eating | 2 | 2019 | 380 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.110 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 220 | 0.110 |
Why?
| | Biopsy | 1 | 2018 | 1130 | 0.110 |
Why?
| | Fibroblasts | 1 | 2019 | 996 | 0.100 |
Why?
| | Proteomics | 1 | 2020 | 1111 | 0.100 |
Why?
| | Adiposity | 2 | 2016 | 518 | 0.100 |
Why?
| | Molecular Dynamics Simulation | 2 | 2025 | 213 | 0.100 |
Why?
| | Weight Gain | 1 | 2017 | 519 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1738 | 0.100 |
Why?
| | Aging | 1 | 2024 | 1865 | 0.100 |
Why?
| | Virus Activation | 2 | 2024 | 88 | 0.100 |
Why?
| | Repressor Proteins | 1 | 2016 | 427 | 0.100 |
Why?
| | Ovary | 1 | 2014 | 221 | 0.100 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 2 | 2009 | 59 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1096 | 0.100 |
Why?
| | Actins | 1 | 2014 | 416 | 0.090 |
Why?
| | Appetite | 1 | 2012 | 69 | 0.090 |
Why?
| | Endometrium | 1 | 2011 | 58 | 0.090 |
Why?
| | Epithelium | 1 | 2012 | 313 | 0.090 |
Why?
| | Nose | 2 | 2021 | 67 | 0.090 |
Why?
| | Blood Vessels | 1 | 2012 | 187 | 0.090 |
Why?
| | Liver Transplantation | 1 | 2019 | 871 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2760 | 0.090 |
Why?
| | Models, Biological | 3 | 2017 | 1783 | 0.080 |
Why?
| | Pelvic Pain | 1 | 2010 | 34 | 0.080 |
Why?
| | MicroRNAs | 2 | 2024 | 692 | 0.080 |
Why?
| | Electron Transport | 1 | 2009 | 115 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 49 | 0.080 |
Why?
| | Hyaluronan Receptors | 1 | 2009 | 102 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 1 | 2021 | 3577 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 91 | 0.080 |
Why?
| | Protein Binding | 2 | 2025 | 2224 | 0.080 |
Why?
| | Viremia | 2 | 2021 | 138 | 0.080 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2011 | 177 | 0.070 |
Why?
| | Male | 9 | 2024 | 67906 | 0.070 |
Why?
| | Lactation | 1 | 2009 | 181 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2012 | 860 | 0.070 |
Why?
| | Signal Transduction | 2 | 2021 | 5081 | 0.070 |
Why?
| | Genetic Variation | 1 | 2012 | 991 | 0.070 |
Why?
| | Feeding Behavior | 1 | 2012 | 655 | 0.070 |
Why?
| | Body Weight | 3 | 2017 | 985 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1062 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2009 | 1317 | 0.060 |
Why?
| | Histones | 1 | 2011 | 636 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2021 | 3018 | 0.060 |
Why?
| | Sleep | 1 | 2010 | 755 | 0.050 |
Why?
| | Varicella Zoster Virus Infection | 1 | 2024 | 24 | 0.050 |
Why?
| | Virus Latency | 1 | 2024 | 80 | 0.050 |
Why?
| | CD11c Antigen | 1 | 2024 | 41 | 0.050 |
Why?
| | Aged | 1 | 2024 | 24001 | 0.050 |
Why?
| | Protein Domains | 1 | 2025 | 289 | 0.050 |
Why?
| | Gene Expression | 3 | 2014 | 1502 | 0.050 |
Why?
| | Sensory Receptor Cells | 1 | 2024 | 98 | 0.050 |
Why?
| | Coloring Agents | 1 | 2023 | 87 | 0.050 |
Why?
| | Lipoproteins, HDL | 1 | 2023 | 77 | 0.050 |
Why?
| | Alveolar Epithelial Cells | 1 | 2024 | 114 | 0.050 |
Why?
| | Apolipoprotein C-III | 1 | 2022 | 12 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2024 | 367 | 0.050 |
Why?
| | Oligonucleotides, Antisense | 1 | 2022 | 112 | 0.050 |
Why?
| | Binding Sites | 1 | 2025 | 1303 | 0.050 |
Why?
| | GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2021 | 17 | 0.050 |
Why?
| | Middle Aged | 1 | 2024 | 33554 | 0.050 |
Why?
| | Phospholipase C beta | 1 | 2021 | 29 | 0.050 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2021 | 22 | 0.050 |
Why?
| | Protein Conformation | 1 | 2025 | 934 | 0.050 |
Why?
| | Neurotoxins | 1 | 2021 | 29 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2021 | 110 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 78 | 0.040 |
Why?
| | Receptors, Odorant | 1 | 2021 | 32 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2021 | 118 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2427 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 123 | 0.040 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 145 | 0.040 |
Why?
| | Virion | 1 | 2021 | 93 | 0.040 |
Why?
| | Abdomen | 2 | 2012 | 125 | 0.040 |
Why?
| | Vaccines, Attenuated | 1 | 2021 | 132 | 0.040 |
Why?
| | Chemical Precipitation | 1 | 2020 | 37 | 0.040 |
Why?
| | Herpes Zoster | 1 | 2024 | 316 | 0.040 |
Why?
| | Mutation | 2 | 2021 | 3959 | 0.040 |
Why?
| | Benzofurans | 1 | 2019 | 21 | 0.040 |
Why?
| | Animal Structures | 1 | 2019 | 9 | 0.040 |
Why?
| | Microbial Viability | 1 | 2019 | 91 | 0.040 |
Why?
| | Body Fluids | 1 | 2019 | 66 | 0.040 |
Why?
| | Disease Transmission, Infectious | 1 | 2019 | 62 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2021 | 370 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 382 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 361 | 0.040 |
Why?
| | Macrophages, Alveolar | 1 | 2021 | 391 | 0.040 |
Why?
| | Biodiversity | 1 | 2021 | 409 | 0.040 |
Why?
| | Receptors, Chemokine | 1 | 2017 | 47 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 903 | 0.030 |
Why?
| | Chylomicron Remnants | 1 | 2017 | 1 | 0.030 |
Why?
| | Calorimetry | 1 | 2017 | 70 | 0.030 |
Why?
| | Hydrolysis | 1 | 2017 | 177 | 0.030 |
Why?
| | Risk Factors | 1 | 2011 | 10407 | 0.030 |
Why?
| | Dependovirus | 1 | 2017 | 68 | 0.030 |
Why?
| | Ecosystem | 1 | 2021 | 596 | 0.030 |
Why?
| | Ceramides | 1 | 2017 | 118 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2022 | 744 | 0.030 |
Why?
| | Calorimetry, Indirect | 1 | 2016 | 84 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2017 | 366 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2017 | 390 | 0.030 |
Why?
| | Gene Deletion | 1 | 2017 | 391 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2057 | 0.030 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2015 | 26 | 0.030 |
Why?
| | DNA | 1 | 2021 | 1459 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2017 | 364 | 0.030 |
Why?
| | Algorithms | 2 | 2012 | 1704 | 0.030 |
Why?
| | Time Factors | 2 | 2017 | 6834 | 0.030 |
Why?
| | Adult | 4 | 2022 | 38023 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 477 | 0.030 |
Why?
| | Homeostasis | 1 | 2017 | 621 | 0.030 |
Why?
| | Spleen | 1 | 2015 | 514 | 0.020 |
Why?
| | Vaccination | 1 | 2021 | 1381 | 0.020 |
Why?
| | Weaning | 1 | 2012 | 47 | 0.020 |
Why?
| | Peritoneum | 1 | 2012 | 44 | 0.020 |
Why?
| | Systole | 1 | 2012 | 189 | 0.020 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2012 | 63 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2011 | 15 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2012 | 204 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2014 | 844 | 0.020 |
Why?
| | Reference Standards | 1 | 2012 | 186 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 2167 | 0.020 |
Why?
| | Femoral Artery | 1 | 2012 | 179 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2012 | 202 | 0.020 |
Why?
| | Peritoneal Diseases | 1 | 2010 | 4 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4193 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2011 | 133 | 0.020 |
Why?
| | Femur | 1 | 2012 | 254 | 0.020 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2010 | 87 | 0.020 |
Why?
| | Intestinal Obstruction | 1 | 2010 | 51 | 0.020 |
Why?
| | Preoperative Care | 1 | 2012 | 362 | 0.020 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2009 | 22 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1316 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 58 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2009 | 117 | 0.020 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2009 | 46 | 0.020 |
Why?
| | Vasodilation | 1 | 2012 | 499 | 0.020 |
Why?
| | Laparoscopy | 1 | 2012 | 466 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2012 | 915 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 843 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 778 | 0.020 |
Why?
| | Software | 1 | 2011 | 665 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1242 | 0.010 |
Why?
| | Blood Pressure | 1 | 2012 | 1789 | 0.010 |
Why?
| | RNA | 1 | 2011 | 921 | 0.010 |
Why?
| | Chronic Disease | 1 | 2010 | 1794 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2011 | 3569 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2834 | 0.010 |
Why?
| | Biomarkers | 1 | 2009 | 4154 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2009 | 2111 | 0.010 |
Why?
|
|
Bruce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|